Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Richard Brodie

Internal Medicine Brookline, MA Medical Doctor

NPI 1912900473 CMS profile 358890

1180 Beacon St, Brookline, MA 02446

Open in the dashboard

General payments

$4,753

89 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Richard Brodie of Brookline, MA is reported in the CMS Open Payments database as having received $4,753 across 89 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $647 5
2020 General $564 12
2019 General $3,542 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Brodie
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Richard Brodie were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Richard Brodie Internal Medicine median Middle half National median
2019 $3,542 $159 $48–$570 $163
2020 $564 $119 $33–$402 $114
2021 $647 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AbbVie, Inc. $1,280 14 payments
  2. AstraZeneca Pharmaceuticals LP $810 19 payments
  3. GlaxoSmithKline, LLC. $581 12 payments
  4. Amgen Inc. $363 3 payments
  5. Janssen Pharmaceuticals, Inc $249 7 payments
  6. Lilly USA, LLC $225 6 payments
  7. Celgene Corporation $222 2 payments
  8. Exactech, Inc. $177 1 payment
  9. Pfizer Inc. $174 9 payments
  10. Allergan Inc. $132 2 payments
  11. Other $538 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $4,738 87 payments
  2. Education $14 2 payments
Products named General payments · program years 2019–2021
  1. FARXIGA $402 8 payments
  2. RINVOQ $353 4 payments
  3. HUMIRA $300 3 payments
  4. TRELEGY ELLIPTA $279 6 payments
  5. Otezla $222 2 payments
  6. EQUINOXE $177 1 payment
  7. SYMBICORT $165 9 payments
  8. INVOKANA $164 3 payments
  9. FASENRA $124 1 payment
  10. EVENITY $123 1 payment
  11. Other $1,876 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

6,947

Median for Internal Medicine: 777

Drug cost

$664,320

Median for Internal Medicine: $73,373

Branded share of claims

18.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 135 $146,564
Mounjaro Tirzepatide Brand 76 $102,590
Eliquis Apixaban Brand 97 $95,603
Ozempic Semaglutide Brand 49 $59,466
Xarelto Rivaroxaban Brand 36 $44,053
Trulicity Dulaglutide Brand 32 $42,387
Farxiga Dapagliflozin Propanediol Brand 20 $18,881
Rybelsus Semaglutide Brand 11 $16,821
Myrbetriq Mirabegron Brand 27 $14,317
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $10,016

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$136,556

Of which drugs: $3,769

Medicare patients

358

Average age 76

Services billed

2,213

181 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 39%
Depression 23%
Diabetes 20%
Chronic kidney disease 18%
Ischemic heart disease 16%
Atrial fibrillation 15%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 21 21 $1,718

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

89 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record